Although most of the clinical trials that investingated the combination of tariquidar with anticancer drugs to improve the therapeutic outcome in cancer patients are closed, tariquidar is still considered as an appropriate compounds for testing the role of P-gp in resistant cancer cells [50]. Here, PGP is linked to cancer.